Erchonia Expands Presence in Europe with Erchonia Laser Ltd.

Press Releases concerning clinical trial results are intended to inform interested parties of the advancements of laser technology in process, not to imply new indications for use. Erchonia supports only those indications for use, cleared by the FDA via 510(k).

McKinney, TX – November 5, 2013 – Erchonia, the global leader in low level laser healthcare applications, today announces the company is expanding with a London-based team, Erchonia Laser Ltd.

This experienced management and sales team will handle European sales for all of Erchonia’s laser products including Zerona, Lunula, Verju, and the new XLR8 handheld device.

Steven Shanks, president of Erchonia, comments, “We are excited to expand the Erchonia brand in Europe. The research supporting Erchonia’s lasers and their level of technological advancement make them exceptionally-suited to the European market. The added focus of a dedicated direct sales staff will help fuel an even stronger growth projection for Erchonia in 2014.”

For more information, please visit

About Erchonia
Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years, Erchonia has been conducting research and development with the world’s leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven safe and effective through independent level 1 clinical trials. Erchonia has garnered eight FDA 510 (k) market clearances and has several other products in research and development for new applications. Currently thousands of Erchonia’s lasers are used daily to reduce body fat, eliminate pain, and treat acne. For additional information, visit

Contact: Katie Cycan
Crier Communications
310-274-1072 x 207